Kolanticon product information
For UK healthcare professionals only
Kolanticon offers triple action relief for IBS
What is Kolanticon?
Kolanticon is the first treatment in the UK to be approved for irritable bowel syndrome (IBS) in many years. Specifically, it is approved for the
treatment and prophylaxis of:
- Smooth muscle spasm, including IBS
- Peptic ulcer and functional dyspepsia symptoms, especially in patients in whom gastric distress results from hyperacidity
- Flatulence
Kolanticon is also indicated for the symptomatic relief of:
- Oesophagitis
- Hiatus hernia
- Gastritis (including iatrogenic gastritis)
Who can use Kolanticon?
Kolanticon is suitable for use in a wide range of patients, including those who are gluten or lactose intolerant. Kolanticon is sugar-free, low in sodium, and contains a synthetic alcohol.
What active ingredients does Kolanticon contain?
Kolanticon is a white viscous suspension. Each 5 ml dose contains:
- 2.5 mg dicycloverine hydrochloride
- 200 mg aluminum hydroxide
- 100 mg light magnesium oxide
- 30 mg simethicone
- What is the recommended dose?
The recommended dose is to take two to four 5 ml spoonfuls every four hours as required.
Who can prescribe Kolanticon?
Kolanticon is available for the treatment of IBS symptoms without a prescription, as a pharmacy only medicine.
What are the main benefits in IBS?
Kolanticon offers a triple-action approach to treating the symptoms of IBS. Dicycloverine is an antispasmodic agent that helps ease abdominal cramping and discomfort. Simethicone is an antiflatulent agent that relieves bloating and excess intestinal gas leading to flatulence. Aluminum hydroxide and magnesium oxide are antacids and help reduce dyspeptic symptoms, which are often associated with IBS.
What are the main side effects?
The main side effects seen with Kolanticon are common with many antispasmodics and are due to the antimuscarinic action of dicycloverine. These include dry mouth, blurred vision, urinary retention and constipation in some patients. Please see the Summary of Product Characteristics (SPC) for a full list of possible adverse events and contraindications/warnings on usage.
For more healthcare professional information
|
Kolanticon offers triple action relief for IBS |
|
|
What is Kolanticon?
Kolanticon is the first treatment in the UK to be approved for irritable bowel syndrome (IBS) in many years. Specifically, it is approved for the
treatment and prophylaxis of:
 |
Smooth muscle spasm, including IBS |
|
|
Peptic ulcer and functional dyspepsia symptoms, especially in patients in whom gastric distress results from hyperacidity |
|
|
Flatulence |
Kolanticon is also indicated for the symptomatic relief of:
|
|
Oesophagitis |
|
|
Hiatus hernia |
|
|
Gastritis (including iatrogenic gastritis) |
Who can use Kolanticon?
Kolanticon is suitable for use in a wide range of patients, including those who are gluten or lactose intolerant. Kolanticon is sugar-free, low in sodium, and contains a synthetic alcohol.
What active ingredients does Kolanticon contain?
Kolanticon is a white viscous suspension. Each 5 ml dose contains:
|
|
2.5 mg dicycloverine hydrochloride |
|
|
200 mg aluminum hydroxide |
|
|
100 mg light magnesium oxide |
|
|
30 mg simethicone |
What is the recommended dose?
The recommended dose is to take two to four 5 ml spoonfuls every four hours as required.
Who can prescribe Kolanticon?
Kolanticon is available for the treatment of IBS symptoms without a prescription, as a pharmacy only medicine.
What are the main benefits in IBS?
Kolanticon offers a triple-action approach to treating the symptoms of IBS. Dicycloverine is an antispasmodic agent that helps ease abdominal cramping and discomfort. Simethicone is an antiflatulent agent that relieves bloating and excess intestinal gas leading to flatulence. Aluminum hydroxide and magnesium oxide are antacids and help reduce dyspeptic symptoms, which are often associated with IBS.
What are the main side effects?
The main side effects seen with Kolanticon are common with many antispasmodics and are due to the antimuscarinic action of dicycloverine. These include dry mouth, blurred vision, urinary retention and constipation in some patients. Please see the Summary of Product Characteristics (SPC) for a full list of possible adverse events and contraindications/warnings on usage.
For more healthcare professional information